|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2007-2-15
|
|
pubmed:abstractText |
The incidence of malignant melanoma is increasing worldwide and patients are being diagnosed earlier with thinner primary lesions. Most patients with very thin melanoma (Breslow thickness < 0.76 mm) are cured by surgery but 2-18% relapse locally or with distant metastases.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
0007-0963
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
156
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
440-7
|
|
pubmed:meshHeading |
pubmed-meshheading:17300231-Adult,
pubmed-meshheading:17300231-Aged,
pubmed-meshheading:17300231-Aged, 80 and over,
pubmed-meshheading:17300231-Antigens, CD95,
pubmed-meshheading:17300231-Cyclin-Dependent Kinase Inhibitor p16,
pubmed-meshheading:17300231-Fas Ligand Protein,
pubmed-meshheading:17300231-Female,
pubmed-meshheading:17300231-Humans,
pubmed-meshheading:17300231-Lectins,
pubmed-meshheading:17300231-Male,
pubmed-meshheading:17300231-Melanoma,
pubmed-meshheading:17300231-Middle Aged,
pubmed-meshheading:17300231-Neoplasm Proteins,
pubmed-meshheading:17300231-Severity of Illness Index,
pubmed-meshheading:17300231-Skin Neoplasms,
pubmed-meshheading:17300231-Tumor Markers, Biological
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
Expression of p16, CD95, CD95L and Helix pomatia agglutinin in relapsing and nonrelapsing very thin melanoma.
|
|
pubmed:affiliation |
Department of Dermatology, Imperial College School of Medicine (START Laboratories), Chelsea and Westminster Hospital, London, UK. louise.fearfield@royalberkshire.nhs.uk
|
|
pubmed:publicationType |
Journal Article,
Multicenter Study
|
